A composite prognostic model for overall survival (OS) based on residual cancer burden (RCB) and tumor-infiltrating lymphocytes (TILs) on residual disease (RCB+TIL) in HER2+ breast cancer patients treated with neoadjuvant therapy: a multicenter study
Federica Miglietta(University of Padua), M.V. Dieci(University of Padua), B. Fernandes(Humanitas University), M. Fassan(University of Padua), Daniela Iannaccone(University of Padua), E. Gasparini(Azienda Sanitaria Unità Locale di Reggio Emilia), F. Porra(University of Padua), Valentina Guarneri(Istituto Oncologico Veneto), A. Bisagni(Azienda Sanitaria Unità Locale di Reggio Emilia), G. Zarrilli(University of Padua), Giancarlo Bisagni, L. Dore(Humanitas University), M. Ragazzi(Azienda Sanitaria Unità Locale di Reggio Emilia), Mireia Mele(University of Padua), G. Griguolo(Istituto Oncologico Veneto), M. Gaudio(Humanitas University), Saverio Coiro(Azienda Sanitaria Unità Locale di Reggio Emilia), M. Bottosso, D. Massa(Istituto Oncologico Veneto), A. Zambelli(Humanitas University)
Cited by 0
Related Papers
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer
|Journal of Clinical Oncology|2007|290
Evolution of HER2-low expression from primary to recurrent breast cancer
|npj Breast Cancer|2021|226